Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABN202
- Development stage
- Preclinical
- Lead developer
- Abion
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
ABN202 is an antibody-cytokine fusion protein (ACFP) designed to overcome the limitations of traditional type I interferons (IFNs) in cancer therapy. It consists of a glycoengineered IFN-β mutein, which exhibits improved biophysical properties and retained functional activity under acidic tumor microenvironment (TME) conditions, fused to a TROP2-targeting monoclonal antibody. This design enables tumor-selective delivery of the IFN-β mutein, enhancing its anti-tumor efficacy while improving the preclinical toxicity profile compared to other type I IFNs. ABN202 induces potent direct tumor cell killing and enhances immune cell-mediated cytotoxicity by activating type I IFN signaling.
- Other names
- αTROP2
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on ABN202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABN202.